← Leaderboards
Mark Aaron Greiner
University Of Iowa
$408,681
Attributed
$1,013,606
Total exposure
2
Grants
2
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $588.7K · FY2022–25$1M$750K$500K$250K$0
'22
'23
'24
'25
Funding mix
By agency
NIH$1,013,606 · 2
By mechanism
R01$588,731 · 1
R21$424,875 · 1
Top collaborators
- Aliasger K Salem3 shared
- Sara Michelle Thomasy1 shared
Most similar at University Of Iowa
Same institution · by research overlap
- Jeffrey E Pessin$38,223,856
- Lois S Weisman$22,745,038
- William Michael Nauseef$12,943,742
- Robert C Piper$10,560,032
- Sarah K. England$13,933,864
Others in their field
Other Rising Stars on “Extracellular Matrix”
- Edwin Manuel · Beckman Research Institute/City Of Hope$3,382,655
- Yanhong Guo · University Of Michigan At Ann Arbor$3,191,698
- Rudy Paladini · Halo Biosciences, Inc.$2,993,376
- Michael B Albro · Boston University (Charles River Campus)$2,974,484
- Caroline Uhler · Broad Institute, Inc.$2,967,486
- Osama Al Dalahmah · Columbia University Health Sciences$2,957,210
Research focus
Extracellular MatrixIn VitroDisease ProgressionEndotheliumFuchs&AposInvestigationCorneal EndotheliumDepositionEarly OnsetEndothelial DystrophyCellsFrequenciesHigh PrevalenceInnovationClinical TrialsCorneaBlindnessAlternative TreatmentAmericanEarly DiagnosisEndothelial CellsCell DeathAffectKeratoplasty
Grant awards (3)
Modulating Ferroptosis in Fuchs Endothelial Corneal Dystrophy$588,731
R01 · FY2025 · EY · contact PI
Optimizing Rho-associated kinase inhibitors for use in treating Fuchs endothelial corneal dystrophy$193,125
R21 · FY2023 · EY · contact PI
Optimizing Rho-associated kinase inhibitors for use in treating Fuchs endothelial corneal dystrophy$231,750
R21 · FY2022 · EY · contact PI